Efficacy of posaconazole in a murine model of central nervous system aspergillosis

Antimicrobial Agents and Chemotherapy
Jackie ImaiDavid A Stevens

Abstract

Human central nervous system (CNS) aspergillosis has >90% mortality. We compared posaconazole with other antifungals for efficacy against murine CNS aspergillosis. All tested regimens of posaconazole were equivalent to those of amphotericin B and superior in prolonging survival and reducing CFU to those of itraconazole and caspofungin and to vehicle controls. No antifungal regimen effected cure. No toxicity was noted. Overall, posaconazole shows potential for treating CNS aspergillosis.

References

Feb 1, 1992·Antimicrobial Agents and Chemotherapy·J S HostetlerD A Stevens
Nov 1, 1990·Reviews of Infectious Diseases·D W Denning, D A Stevens
Sep 1, 1995·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·L H HansonD A Stevens
Nov 22, 1997·Diagnostic Microbiology and Infectious Disease·D A Stevens, B H Aristizabal
Jan 8, 1998·The Journal of Antimicrobial Chemotherapy·D W Denning
Aug 13, 1998·The Journal of Antimicrobial Chemotherapy·K L OakleyD W Denning
Nov 18, 1998·The Journal of Antimicrobial Chemotherapy·J R GraybillD Loebenberg
Apr 9, 1999·Clinical Microbiology Reviews·J P Latgé
Feb 19, 2000·Antimicrobial Agents and Chemotherapy·W R KirkpatrickT F Patterson
Apr 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D A StevensG A Pankey
Nov 4, 2000·Expert Opinion on Investigational Drugs·M A Hossain, M A Ghannoum
Dec 20, 2000·Antimicrobial Agents and Chemotherapy·S ArikanJ H Rex
Feb 24, 2001·Medical Mycology·T J WalshF C Odds
Feb 27, 2001·The Journal of Antimicrobial Chemotherapy·E DannaouiF Persat
Aug 23, 2001·International Journal of Antimicrobial Agents·K UchidaH Yamaguchi
Sep 11, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D CaillotK De Beule
Dec 6, 2001·The Journal of Antimicrobial Chemotherapy·F BarchiesiG Scalise
May 29, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ingo K MellinghoffGary J Schiller
Jul 19, 2002·Transplant Infectious Disease : an Official Journal of the Transplantation Society·C A SableM J DiNubile
Aug 9, 2002·The New England Journal of Medicine·Raoul HerbrechtUNKNOWN Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillu
Aug 27, 2002·The Journal of Infectious Diseases·Tom M ChillerDavid A Stevens
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Tom M ChillerDavid A Stevens
Feb 21, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Leonard B Johnson, Carol A Kauffman
May 6, 2004·Annals of Hematology·X Schiel

❮ Previous
Next ❯

Citations

Jul 3, 2007·Acta Neuropathologica·Stefan ZimmerliStephen L Leib
Mar 4, 2009·Medical Mycology·S Schwartz, E Thiel
Dec 5, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshJohn R Perfect
Oct 7, 2008·The Journal of Antimicrobial Chemotherapy·R Y HachemI I Raad
Dec 5, 2008·The Journal of Antimicrobial Chemotherapy·M Mar RodríguezJosep Guarro
Jan 22, 2005·Current Opinion in Pediatrics·Charalampos Antachopoulos, Thomas J Walsh
Feb 7, 2013·Antimicrobial Agents and Chemotherapy·David A Stevens
Mar 30, 2006·Antimicrobial Agents and Chemotherapy·Karl V ClemonsDavid A Stevens
Feb 1, 2008·Journal of Clinical Microbiology·Guillermo Garcia-EffronDavid S Perlin
Jan 5, 2011·American Journal of Respiratory and Critical Care Medicine·Andrew H LimperUNKNOWN American Thoracic Society Fungal Working Group
Aug 19, 2007·Expert Opinion on Drug Metabolism & Toxicology·Shravan Kethireddy, David Andes
Jul 31, 2007·Future Microbiology·Fedja FarowskiOliver A Cornely
Mar 4, 2009·Expert Review of Anti-infective Therapy·Winter J SmithJohn R Perfect
Aug 19, 2005·Expert Review of Anti-infective Therapy·Andreas H Groll, Thomas J Walsh
Nov 19, 2010·Expert Review of Hematology·Aneesh K Mehta, Amelia A Langston
May 31, 2006·Expert Opinion on Investigational Drugs·George Aperis, Eleftherios Mylonakis
May 23, 2007·Expert Opinion on Pharmacotherapy·Douglas S Kwon, Eleftherios Mylonakis
Jun 19, 2007·Chest·David A StevensJ Richard Graybill
Aug 2, 2011·Mayo Clinic Proceedings·Russell E Lewis
Feb 3, 2007·Médecine et maladies infectieuses·A Paugam
Jul 19, 2011·Mycoses·Aspasia KatragkouTheoklis E Zaoutis
Aug 18, 2012·Diagnostic Microbiology and Infectious Disease·S Krishnan NatesanP H Chandrasekar
Nov 18, 2016·PLoS Neglected Tropical Diseases·Frédéric-Antoine DauchyDerrick R Robinson
Jan 31, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michele I Morris
Sep 24, 2013·Expert Review of Anti-infective Therapy·Seyedmojtaba SeyedmousaviRoger J M Brüggemann
Feb 22, 2013·The Journal of Pharmacology and Experimental Therapeutics·Bénédicte LelièvreBertrand Diquet
May 27, 2005·The Journal of Antimicrobial Chemotherapy·Jackie ImaiDavid A Stevens
Aug 28, 2020·Medical Mycology·Aryse Martins MeloMelissa Orzechowski Xavier
Jul 22, 2005·Drugs·Gillian M Keating

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Central Nervous System Fungal Infections

Central nervous system fungal infections are rare and typically occur in immunocompromised patients, such as those with HIV infection or transplant recipients. Discover the latest research on central nervous system fungal infections here.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.